Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation safety study aims to personalize thyroid cancer treatment

NCT ID NCT03986437

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study collects standard-of-care images from people with differentiated thyroid cancer who are treated with radioactive iodine (Iodine-131). The goal is to better understand how much radiation reaches healthy organs and what dose is needed to destroy thyroid tissue. By gathering this data, researchers hope to develop safer, more personalized treatment plans and support future large-scale studies on the effects of low-dose radiation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Iodine-131
What this could lead to
If successful, this could help doctors personalize Iodine-131 doses to reduce radiation exposure to healthy organs while still effectively treating thyroid cancer.
What could go wrong
This is an observational study that only collects images, not a treatment trial. It may not directly lead to changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

29 people

The number who actually took part.

Started

Jan 2020

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with differentiated thyroid cancer and who are eligible for a Iodine-131 (I-131) treatment after a total thyroidectomy or completion thyroidectomy will be invited to join the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with differentiated thyroid cancer (papillary or follicular) stage T1b, T2, T3A, Nx-N0-N1, M0 (according to AJCC 8th edition, 2017) of intermediate risk of recurrence (according to 2015 ATA Risk Stratification System) 2. Patient is eligible to receive a therapeutic activity of 3.7 GBq of I-131 after total thyroidectomy or completion thyroidectomy 3. Age ≥ 18 years old 4. Patient affiliated to the French social security system 5. Patient who has received an informed consent for the study Exclusion Criteria: 1. Patient who has received an external radiotherapy within 6 weeks prior to I-131 treatment 2. Patient who has received a systemic chemotherapy within 6 weeks prior to I-131 treatment 3. History of treatment with I-131 4. Pregnant or breastfeeding women 5. Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures 6. Patient protected by law

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Differentiated thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Differentiated thyroid cancer

Contacts and locations

Locations

  • IUCT-O

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.